

Special Issue

Analysis and Modification of Existing Vaccines for the Development of Next-Generation Vaccines

Message from the Guest Editor

Dear colleagues, The development of the first vaccine by Edward Jenner, “the father of immunology”, has proven to be one of the greatest innovations, saving countless lives. However, the emergence or recurrence of pathogens is an ongoing threat to humans, not least with the recent occurrence of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the development and distribution of a vaccine against SARS-CoV-2 are urgently needed, other diseases should not be ignored. In this regard, the small modification of existing vaccines is likely to prove efficient for the development of versatile vaccines that are more stable for storage and represents an important step in the direction of the production of next-generation vaccines. This Special Issue will focus on the analysis of the mode of action of current vaccines and their modification for the development of next-generation vaccines. The submission of articles covering the following research areas is encouraged:

- Experimental characterization of vaccine;
- Proof of concept of next-generation vaccines.

Guest Editor

Dr. Takashi Imai

1. Department of Microbiology, Saitama Medical University, Saitama, Japan
2. Department of Infectious Diseases and Host Defense, Gunma University, Gunma, Japan

Deadline for manuscript submissions

closed (30 June 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/60721

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).